Pharmacotherapy for Irritable Bowel Syndrome
AbstractIrritable bowel syndrome (IBS) is a disorder of the brain-gut axis; the pathophysiological mechanisms include altered colonic motility, bile acid metabolism, neurohormonal regulation, immune dysfunction, alterations in the epithelial barrier and secretory properties of the gut. This article reviews the mechanisms, efficacy, and safety of current pharmacotherapy, and medications that are in phase III trials for the treatment of IBS. There remains a significant unmet need for effective treatments—particularly for the pain component of IBS—although the introduction of drugs directed at secretion, motility and a non-absorbable antibiotic provide options for the bowel dysfunction in IBS. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Camilleri, M.; Ford, A.C. Pharmacotherapy for Irritable Bowel Syndrome. J. Clin. Med. 2017, 6, 101.
Camilleri M, Ford AC. Pharmacotherapy for Irritable Bowel Syndrome. Journal of Clinical Medicine. 2017; 6(11):101.Chicago/Turabian Style
Camilleri, Michael; Ford, Alexander C. 2017. "Pharmacotherapy for Irritable Bowel Syndrome." J. Clin. Med. 6, no. 11: 101.